SelvitaWAR:SLV +3.27%81 EBITDA Margin % is 13.35% as of Mar. 2026, which is 22% below its 10-year median of 17.20. GuruFocus rates WAR:SLV with a GF Score™ of 81/100 and a GF Value™ of zł58.46 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Selvita ranks better than 68.14% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Selvita's EBITDA for the
three
months ended in Mar. 2026 was zł10.1 Mil. Selvita's Revenue for the
three
months ended in Mar. 2026 was zł75.8 Mil. Therefore, Selvita's EBITDA margin for the quarter that ended in Mar. 2026 was 13.35%.
Selvita (WAR:SLV) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Selvita EBITDA Margin % Related Terms
Selvita EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Selvita's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SLV vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Selvita's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selvita EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Selvita's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Selvita's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selvita (WAR:SLV) has a EBITDA Margin % of 13.35% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Selvita and its competitors. This is 22% below median its historical median of 17.20. Over the past decade, Selvita's EBITDA Margin % has ranged from 4.94 to 35.62. According to the industry distribution chart, Selvita ranks #65 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 31.9%.
Is Selvita's EBITDA Margin % too high?
Selvita's current EBITDA Margin % of 13.35% is 22% below median its 10-year median of 17.20. Over the past 10 years, this metric has ranged from a low of 4.94 to a high of 35.62. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Selvita's value of 13.35% is 156.7% above this industry median. Based on the distribution chart, Selvita ranks #65 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Selvita has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Selvita's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Selvita ranks #65 out of 204 companies for EBITDA Margin %. This puts Selvita in the upper half of its industry. The industry median EBITDA Margin % is 5.20. Selvita's value of 13.35% is 156.7% above this benchmark. Historically, Selvita's own EBITDA Margin % has ranged from 4.94 to 35.62 over the past decade. While the company's 10-year median is 17.20 vs. the industry median of 5.20, Selvita has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Selvita's current EBITDA Margin % of 13.35% is 156.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Selvita and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selvita's current EBITDA Margin % is 13.35%, which is 22% below median its own 10-year median of 17.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selvita stock overvalued right now?
Based on GuruFocus' analysis, Selvita (WAR:SLV) is currently considered Significantly Undervalued. The stock's GF Value™ is zł58.46, compared to a current price of zł31.60 — trading 45.9% below its estimated fair value. The current EBITDA Margin % is 13.35%, which is 22% below median its 10-year median of 17.20 and 156.7% above the Medical Diagnostics & Research industry median of 5.20. Selvita's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Selvita (WAR:SLV), the current EBITDA Margin % is 13.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selvita (WAR:SLV) Overvalued in 2026?
Based on GuruFocus' analysis, Selvita stock appears to be undervalued.
The current stock price of zł31.60 is trading 45.9% below its estimated GF Value™ of zł58.46.
GuruFocus considers Selvita to be Significantly Undervalued.
Key valuation signals for WAR:SLV:
EBITDA Margin %: 13.35% (22% below median its 10-year median of 17.20)
GF Value™: zł58.46 vs. price of zł31.60 (45.9% below fair value)
Industry Position: 156.7% above the Medical Diagnostics & Research median (#65 of 204)
No single metric tells the full story. See the WAR:SLV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects.
81GF Score
Get the complete analysis for WAR:SLV
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SLV has been successfully added to your 
